(NASDAQ: KLRS) Kalaris Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.12%.
Kalaris Therapeutics's earnings in 2025 is -$58,769,000.On average, 1 Wall Street analyst forecast KLRS's earnings for 2025 to be -$11,801,455, with the lowest KLRS earnings forecast at -$11,801,455, and the highest KLRS earnings forecast at -$11,801,455.
In 2026, KLRS is forecast to generate -$12,810,127 in earnings, with the lowest earnings forecast at -$12,810,127 and the highest earnings forecast at -$12,810,127.